Xenon Pharmaceuticals Inc.XENE
What Xenon Pharmaceuticals Inc. does.
We are a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. We are advancing a differentiated product pipeline led by our investigational candidate, azetukalner, which is being studied in multiple Phase 3 studies in epilepsy, major depressive disorder, or MDD, and bipolar depression, or BPD. Our early-stage pipeline includes Kv7 potassium channel openers and Nav sodium channel modulators being advanced for select high‑need indications, including pain.
Our goal is to build a fully-integrated and profitable biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics to treat a range of neurological and psychiatric disorders.
• Leveraging our discovery capabilities – which were founded upon our understanding of the genetics of channelopathies combined with proprietary biology and medicinal chemistry assets and know-how – to identify product candidates for development;
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $32.2M | $18.4M | $9.4M | $0 | $0 | $7.5M |
| Net income | -$28.8M | -$78.9M | -$125.4M | -$182.4M | -$234.3M | -$345.9M |
| Free cash flow | -$50.8M | -$71.6M | -$103.9M | -$156.7M | -$184.5M | -$279.9M |
More on XENE.
- Xenon Pharmaceuticals Inc. summary
- Xenon Pharmaceuticals Inc. financial statements
- Xenon Pharmaceuticals Inc. key metrics
- Xenon Pharmaceuticals Inc. health scores and style box
- Xenon Pharmaceuticals Inc. earnings
- Xenon Pharmaceuticals Inc. dividends
- Xenon Pharmaceuticals Inc. valuation
- Xenon Pharmaceuticals Inc. ownership and insiders
- Xenon Pharmaceuticals Inc. peers
Figures from Xenon Pharmaceuticals Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.